Active substances: Ciprofloxacin
They observed no differences between treated and untreated episodes when comparing progression to symptomatic UTI.
Green et al. A prospective randomized trial performed by Moradi et al. In their study, 96 50.
According to their protocol, all episodes of AB were systematically screened and treated. Risk factors for AB were female sex, glomerulonephritis as the disease that led to transplantation, and double renal transplant.
The incidence of pyelonephritis in these patients was 7. The detection of two or more episodes of AB was statistically associated with pyelonephritis.
Nevertheless, renal function was similar to the group of patients who did not present AB during follow-up. Their data suggest that there are no differences in renal allograft prognosis between patients who do not develop AB and those who do develop AB and are systematically treated during the first three years after transplantation.
There are some ongoing trials to try to answer this question. Against B. Moxifloxacin was least active against Fusobacterium species other than F.
Citron and Appleman tested 217 anaerobic bacteria recovered from patients with intra-abdominal infections. Edminston et al.
In this study, moxifloxacin's MIC 90 for B. The MIC 90 of this fluoroquinolone for isolates of B.
It was least active against isolates of B. Horn and Robson noted that moxifloxacin had relatively poor activity against 200 B. More recently, Goldstein et al. Species variation was observed, with Bacteroides uniformis, Bacteroides vulgatus, Clostridium clostridiiforme, and Clostridium symbiosum being least susceptible and accounting for most of the resistant isolates.
Only 1 isolate of B. Gatifloxacin has also been studied against a large number of anaerobic bacteria, including those associated with intra-abdominal infections, and exhibited in vitro activity similar to that of moxifloxacin.
Gemifloxacin was found to be considerably less active than the methoxyfluoroquinolones against many Bacteroides group isolates.
In this study, the MIC 90 s of this agent against isolates of B.
Gemifloxacin does exhibit in vitro activity as good as or better than that of moxifloxacin against Peptostreptococcus, Porphyromonas, and Fusobacterium species. Aldridge et al. The older fluoroquinolones e.
They rank fourth as causes of intensive care unit ICU acquired pneumonia, fifth as causes of ICU acquired bacteremia and sixth as causes of ICU acquired urinary tract infection 225. The classic clinical presentation is dramatic: toxic presentation with sudden onset of high fever and hemoptysis currant jelly sputum.